Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

  • This share is currently suspended. It was suspended at a price of 37.50
  • There is currently no data for CAT

Portfolio Update

25 Jan 2016 07:00

RNS Number : 7993M
CATCo Reinsurance Opps Fund Ltd
25 January 2016
 

 

 

 

CATCo Reinsurance Opportunities Fund Ltd. ("the Company")

Portfolio Update

 

To: SFM, London Stock Exchange and Bermuda Stock Exchange

 

Date: 25 January 2016

 

Highlights

· The FY15 net asset value ("NAV") return was 11.58%, outperforming the Eurekahedge Insurance Linked Securities Advisors Index of 4.27%

· Side pockets set up at 31 December 2015 amount to approximately 5.5% of Ordinary Share NAV with a significant proportion of this amount related to the late December 2015 UK flooding event. This event is not expected to result in loss payments diluting the value of these side-pockets

· The late December UK flooding and US tornado events also necessitated the need for a conservative reserving approach at year-end, which adversely impacted the NAV by 175 bps. However, the expectation is that a significant proportion of this reserve will be released during 2016

· There are no remaining side pockets associated with calendar years prior to 2014 as Superstorm Sandy has now been fully commuted during Q4 2015 resulting in approximately a 1% increase to the FY15 NAV

· The side pockets related to 2014's US convective storms have reduced to c. 1.5% from the 3.5% established at 31 December 2014

· Increased demand for Markel CATCo Re Ltd (the "Reinsurer") products has led to 100% of available capital deployed at 1 January 2016

· FY16 portfolio provides for an indicative net return of c. 16% on invested capital with a lower risk portfolio versus FY15's portfolio

· Average risk of FY16 portfolio down c. 20% on FY15's portfolio

· Maximum capital exposed to a worst case single event is not more than 10%

· The FY2015 dividend will be announced on 29 January 2016

 

 

For further information:

 

Judith Wynne,

Company Secretary and General Counsel

Markel CATCo Investment Management Ltd

Telephone: +1 441 493 9005

Email: judith.wynne@markelcatco.com

 

Mark Way

Fund Operations and Investor Relations Director

Markel CATCo Investment Management Ltd

Telephone: +1 441 493 9003

Email: mark.way@markelcatco.com

 

David Benda / Hugh Jonathan

Numis Securities Limited

Telephone: +44 (0) 20 7260 1000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PFUBUGDBDBDBGLX
Date   Source Headline
13th Jun 20064:50 pmRNSRule 8.3- Cambridge Antibody
13th Jun 20063:54 pmRNSRule 2.10 Announcement
13th Jun 200612:18 pmRNSEPT Disclosure
13th Jun 200611:42 amRNSEPT Disclosure
13th Jun 200611:35 amRNSEPT Disclosure
13th Jun 200610:20 amRNSEPT Disclosure
12th Jun 20065:35 pmRNSRule 8.3 - Cambridge Antibody
12th Jun 200612:00 pmRNSEPT Disclosure
12th Jun 200611:34 amRNSEPT Disclosure
12th Jun 200611:14 amRNSRule 8.3- (CAT)
12th Jun 200610:08 amRNSEPT Disclosure
12th Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
9th Jun 20061:30 pmRNSRule 8.3- (CAT)
9th Jun 200612:36 pmRNSEPT Disclosure
9th Jun 200611:56 amRNSEPT Disclosure
9th Jun 200611:54 amRNSEPT Disclosure
9th Jun 200611:38 amRNSRule 8.3-Cambridge Antibody
8th Jun 20064:19 pmRNSRule 2.10 Announcement
8th Jun 20062:21 pmRNSEPT Disclosure
8th Jun 20061:14 pmRNSRule 8.3- (CAT)
8th Jun 200610:49 amRNSEPT Disclosure
7th Jun 20065:01 pmRNSHolding(s) in Company
7th Jun 20064:55 pmRNSRule 8.3- Cambridge Anti Tech
7th Jun 200612:38 pmRNSRule 8.3- (CAT)
7th Jun 200612:08 pmRNSEPT Disclosure
7th Jun 200610:00 amRNSOffer for Cambridge Antibody
6th Jun 20064:01 pmRNSRule 8.3- Cambridge Antibody
6th Jun 20063:45 pmRNSRule 8.3- Cambridge Antibody
6th Jun 200612:43 pmRNSEPT Disclosure
5th Jun 20066:00 pmRNSEPT Disclosure
5th Jun 20061:10 pmRNSRule 8.3- (CAT)
5th Jun 200612:55 pmRNSEPT Disclosure
5th Jun 200611:24 amRNSEPT Disclosure
2nd Jun 20062:14 pmRNSEPT Disclosure
2nd Jun 20061:19 pmRNSRule 8.3- (CAT)
2nd Jun 200612:27 pmRNSEPT Disclosure
2nd Jun 200612:22 pmRNSEPT Disclosure
2nd Jun 20067:00 amRNSRule 8.3- Cambridge Antibody
1st Jun 20064:22 pmRNSRule 8.3- Cambridge Antibody
1st Jun 20063:21 pmRNSHolding(s) in Company
1st Jun 200612:25 pmRNSEPT Disclosure
1st Jun 200611:10 amRNSEPT Disclosure
31st May 20063:13 pmRNSRule 8.3- (CAT)
31st May 20063:00 pmRNSMerger Update
31st May 20061:04 pmRNSRule 8.3- Cambridge Antibody
31st May 200611:43 amRNSEPT Disclosure
31st May 200611:27 amRNSEPT Disclosure
31st May 200611:25 amRNSEPT Disclosure
30th May 20063:25 pmRNSRule 8.3- (CAT)
30th May 20063:16 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.